Endura drugs mRNA before it becomes disease. With a stealth launch, illustrated to the bond.

Endura’s small molecules form a permanent covalent bond with mRNA, so the disease-causing protein is never made: gene-level precision, delivered as a pill. As they prepared to come out of stealth, the science was ready. The challenge was making it land with people meeting Endura for the first time, from investors skimming on a phone to the senior chemists they hoped to hire.










No items found.
We refined their brand, then designed the deck and the launch site. Then we illustrated the science itself: how Endura’s molecules first bind to their target, then bond to it. Every illustration had to be accurate enough for a chemist and clear enough for an investor. Endura came out of stealth with the science intact.










No items found.
Drug development is hard to visualize, there's no physical object to point at. DreamLab drew our science from the literature. The deck and site now let people see what we're building. We really enjoyed working with them.
Adrian Sanborn, CEO and Co-founder of Endura Therapeutics